Personalis
The retrospective results suggest that the test's sensitivity boost over other platforms can overcome the challenge of detecting ctDNA in adenocarcinomas.
Personalis Preliminary Q4 Revenues Dip 15 Percent, Full-Year Revenues Rise 15 Percent
Declining revenues from Natera and the Million Veteran Program put pressure on quarterly revenues, while test and service sales buoyed full-year revenues.
Personalis Nabs $50M Investment From Merck, Extends Collaboration with Moderna
The company extended its collaboration to further advance an investigational personalized vaccine therapy under development by Merck and Moderna.
In Brief This Week: Abbott, Personalis, Aspira Women's Health, Thermo Fisher Scientific, Illumina, More
News items for the week of Nov. 4, 2024.
Tempus AI, Personalis Expand Commercialization Partnership for MRD Test With $36M Investment
Tempus is the exclusive commercial partner for Personalis' minimal residual disease test for breast and lung cancers and for immunotherapy monitoring.
Jun 5, 2024
Dec 6, 2023
Apr 27, 2023
Foresight Diagnostics Closes $58.8M Series B Round
Sep 7, 2022
May 6, 2022